← Back to Screener
Xeris Biopharma Holdings, Inc. Common Stock (XERS)
Price$6.25
Favorite Metrics
Price vs S&P 500 (26W)-29.02%
Price vs S&P 500 (4W)7.60%
Market Capitalization$1.06B
P/E Ratio (Annual)1915.09x
All Metrics
P/CF (Annual)37.06x
Book Value / Share (Quarterly)$0.08
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)38.35%
Cash Flow / Share (Quarterly)$0.17
Price vs S&P 500 (YTD)-22.99%
Gross Margin (TTM)85.41%
Net Profit Margin (TTM)0.19%
EPS (TTM)$-0.02
10-Day Avg Trading Volume1.35M
EPS Excl Extra (TTM)$-0.02
Revenue Growth (5Y)70.26%
EPS (Annual)$0.00
ROI (Annual)0.24%
Gross Margin (Annual)85.41%
Net Profit Margin (5Y Avg)-79.62%
Cash / Share (Quarterly)$0.67
P/E Basic Excl Extra (TTM)1915.09x
Revenue Growth QoQ (YoY)42.78%
P/E Normalized (Annual)1915.09x
ROA (Last FY)0.14%
Revenue Growth TTM (YoY)43.72%
EBITD / Share (TTM)$0.20
ROE (5Y Avg)-295.22%
Operating Margin (TTM)8.53%
Cash Flow / Share (Annual)$0.17
P/B Ratio77.50x
P/B Ratio (Quarterly)97.76x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.01x
Net Interest Coverage (TTM)1.02x
ROA (TTM)0.16%
EV / EBITDA (TTM)32.74x
EPS Incl Extra (Annual)$0.00
Current Ratio (Annual)2.19x
Quick Ratio (Quarterly)1.48x
3-Month Avg Trading Volume1.99M
52-Week Price Return56.13%
EV / Free Cash Flow (Annual)41.90x
P/E Incl Extra (TTM)1915.09x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-0.95
P/S Ratio (Annual)3.64x
Asset Turnover (Annual)0.76x
52-Week High$10.08
Operating Margin (5Y Avg)-69.12%
EPS Excl Extra (Annual)$0.00
CapEx CAGR (5Y)12.87%
26-Week Price Return-20.28%
Quick Ratio (Annual)1.48x
13-Week Price Return-15.96%
Total Debt / Equity (Annual)16.10x
Current Ratio (Quarterly)2.19x
Enterprise Value$1,170.252
Revenue / Share Growth (5Y)28.68%
Asset Turnover (TTM)0.83x
Book Value / Share Growth (5Y)-53.08%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.73x
Pretax Margin (Annual)0.19%
Cash / Share (Annual)$0.67
3-Month Return Std Dev43.56%
Gross Margin (5Y Avg)80.49%
Net Income / Employee (TTM)$0
ROE (Last FY)4.05%
Net Interest Coverage (Annual)1.02x
EPS Basic Excl Extra (Annual)$0.00
P/FCF (TTM)27.87x
Receivables Turnover (TTM)6.38x
EV / Free Cash Flow (TTM)41.90x
Total Debt / Equity (Quarterly)16.10x
EPS Incl Extra (TTM)$-0.02
Receivables Turnover (Annual)6.38x
ROI (TTM)4.73%
P/S Ratio (TTM)3.64x
Pretax Margin (5Y Avg)-80.25%
Revenue / Share (Annual)$1.69
Tangible BV / Share (Annual)$-0.72
Forward P/E48.75x
Price vs S&P 500 (52W)21.03%
P/E Ratio (TTM)1915.09x
Year-to-Date Return-18.85%
5-Day Price Return6.70%
EPS Normalized (Annual)$0.00
ROA (5Y Avg)-20.79%
Net Profit Margin (Annual)0.19%
Month-to-Date Return9.83%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$0.21
Operating Margin (Annual)8.53%
LT Debt / Equity (Annual)16.10x
P/CF (TTM)37.06x
ROI (5Y Avg)-71.13%
P/E Excl Extra (TTM)1915.09x
LT Debt / Equity (Quarterly)16.10x
EPS Basic Excl Extra (TTM)$-0.02
P/B Ratio (Annual)97.76x
Inventory Turnover (TTM)0.73x
Pretax Margin (TTM)0.19%
Book Value / Share (Annual)$0.08
Price vs S&P 500 (13W)-18.83%
Beta0.83x
P/FCF (Annual)37.99x
Revenue / Share (TTM)$1.36
ROE (TTM)80.95%
52-Week Low$3.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XERSXeris Biopharma Holdings, Inc. Common Stock | 3.64x | 43.72% | 85.41% | — | $6.25 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Xeris Biopharma is a commercial-stage biopharmaceutical company specializing in treatments for chronic endocrine and neurological diseases. The company markets three FDA-approved therapies: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its Phase 3-ready pipeline includes XP-8121, a once-weekly subcutaneous levothyroxine injection leveraging the company's proprietary XeriSol technology.